Single Case Study
Show indications (1)
- Anxiety, nonspecific (BF)

Scientific evidence
AAPB, ISNR and BBNS classify the clinical evidence for biofeedback and neurofeedback across five evidence levels.
Updated February 2026
The ratings follow the AAPB/ISNR classification, 4th edition of 2023, and BBNS METID v3.0 of January 2026. On this page, Level 1 is named Single Case Study.
Scientific research on neuro- and biofeedback takes time: controlled studies follow strict methodological standards, are usually focused on single, narrowly defined questions, and therefore only ever capture a fraction of what's actually possible in individualized treatment. In our daily practice, we consistently see noticeably better outcomes across the indications presented here than current research alone would suggest. This is because we tailor every treatment to the individual patient rather than applying a standardized protocol, drawing on multiple effective elements at once: precise qEEG assessment, targeted lifestyle adjustments, psychoeducation, complementary approaches such as photobiomodulation and transcranial microcurrent therapy, and the experience and therapeutic skill of our therapists. This combination — which is difficult to capture in clinical studies for methodological reasons — often makes the decisive difference in practice. That's why we see it as our responsibility to keep you transparently informed about the current state of research, while also going beyond what studies alone can show.
Open a level to see every assigned indication. NF means neurofeedback and BF means biofeedback.
A direct overview of selected ratings. Different methods for the same indication can sit at different levels.
Generalised anxiety disorder is classified at Level 4; panic disorder with biofeedback or neurofeedback is classified at Level 5. The level depends on the specific condition and protocol.
Adult headache is classified at Level 4. This category includes established biofeedback protocols for headache and migraine treatment.
Biofeedback for hypertension is classified at Level 4.
Neurofeedback for epilepsy is classified at Level 4 and is integrated into a specialist-led treatment plan.
Neurofeedback and biofeedback for depression are classified at Level 5.
Neurofeedback for tinnitus is classified at Level 2; biofeedback for tinnitus is classified at Level 3.
Neurofeedback and biofeedback for insomnia are classified at Level 3.
Neurofeedback for ADHD is classified at Level 5.¹
¹ ADHD remains at Level 5 in the AAPB/ISNR and BBNS classification. Methodological controversy relates mainly to blinded outcome measurement.
Neurofeedback and biofeedback combine insights from EEG research, imaging, and clinical neuroscience. In German-speaking countries, the Tübingen research group led by Niels Birbaumer, Ute Strehl, and Ulrike Leins shapes clinical SCP research for ADHD. In Switzerland, Tomas Ros, Patrik Vuilleumier, Dimitri Van De Ville, Olaf Blanke, and Nicolas Gninenko at Geneva’s Campus Biotech and EPFL are among the leading researchers in real-time neurofeedback across Europe; together they organise the international rtFIN conference 2026 in Geneva. In addition, Patrick Neff and Tobias Kleinjung in Zurich, as well as Adrian Guggisberg and the CHUV team in Lausanne, are researching neurofeedback applications for tinnitus and neurorehabilitation. I-NFBF draws on these scientific foundations while combining them with an individually tailored, responsible neurotherapeutic practice.
Quality and safety
Accurate measurement, qualified guidance and the right protocol are central to safe and efficient training.
Consumer EEG devices do not provide the signal quality required for clinical neurofeedback and are particularly susceptible to artefacts. Imprecise signals can lead to inefficient training and poorly targeted protocols.
I-NFBF uses CE-marked medical devices, together with qEEG-guided protocols. This supports precise training plans and structured progress review.
The complete classifications and methodological framework are available from the professional bodies.
We can explain how the levels apply to a particular concern and selected protocol.